Capstone Investment Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$7.4M Buy
57,915
+7,864
+16% +$982K 0.01% 348
2025
Q4
$6.1M Buy
50,051
+28,551
+133% +$3.27M 0.01% 334
2025
Q3
$2.15M Buy
21,500
+4,929
+30% +$444K ﹤0.01% 740
2025
Q2
$1.37M Buy
16,571
+11,287
+214% +$900K ﹤0.01% 756
2025
Q1
$429K Sell
5,284
-7,621
-59% -$681K ﹤0.01% 1111
2024
Q4
$1.16M Buy
+12,905
New +$1.25M ﹤0.01% 1017
2024
Q3
Sell
-29,898
Closed -$2.94M 2243
2024
Q2
$2.77M Buy
+29,898
New +$2.68M 0.01% 617
2023
Q4
Sell
-30,403
Closed -$2.22M 2450
2023
Q3
$2.22M Buy
30,403
+24,468
+412% +$1.95M 0.01% 693
2023
Q2
$494K Sell
5,935
-2,611
-31% -$218K ﹤0.01% 1166
2023
Q1
$651K Buy
8,546
+3,800
+80% +$315K ﹤0.01% 926
2022
Q4
$394K Buy
+4,746
New +$384K ﹤0.01% 1179
2022
Q1
Sell
-88,138
Closed -$9.87M 2170
2021
Q4
$9.87M Buy
88,138
+40,365
+84% +$4.87M 0.02% 612
2021
Q3
$6.01M Buy
47,773
+32,573
+214% +$4.19M 0.01% 795
2021
Q2
$2.06M Buy
+15,200
New +$2M ﹤0.01% 1017

Other funds holding XBI

Capstone Investment Advisors's XBI Position: Q1 2026 in Review

Capstone Investment Advisors increased its State Street SPDR S&P Biotech ETF (XBI) stake by 16% in Q1 2026, buying an estimated $982K and bringing the position to 57,915 shares worth $7.4M. The position accounts for 0.01% of the portfolio, ranked #348.

Capstone Investment Advisors first reported a position in XBI in Q2 2021 and has held it in 14 quarters since. The position peaked at $9.87M in Q4 2021. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

  • Capstone Investment Advisors held 57,915 shares of State Street SPDR S&P Biotech ETF worth $7.4M as of Q1 2026.
  • Capstone Investment Advisors bought 7,864 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $982K.
  • State Street SPDR S&P Biotech ETF made up 0.01% of Capstone Investment Advisors's portfolio in Q1 2026, its #348 holding.
  • Capstone Investment Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q2 2021 and has held it in 14 quarters since.
  • Capstone Investment Advisors's State Street SPDR S&P Biotech ETF position peaked at $9.87M in Q4 2021.
  • 813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Capstone Investment Advisors's 13F filing for Q1 2026, filed 15 May 2026.